IL250525B - Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives - Google Patents

Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives

Info

Publication number
IL250525B
IL250525B IL250525A IL25052517A IL250525B IL 250525 B IL250525 B IL 250525B IL 250525 A IL250525 A IL 250525A IL 25052517 A IL25052517 A IL 25052517A IL 250525 B IL250525 B IL 250525B
Authority
IL
Israel
Prior art keywords
preparation
synthetic intermediates
tetrahydroquinoline derivatives
tetrahydroquinoline
derivatives
Prior art date
Application number
IL250525A
Other languages
English (en)
Hebrew (he)
Other versions
IL250525A0 (en
Original Assignee
Dezima Pharma B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51429345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL250525(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dezima Pharma B V filed Critical Dezima Pharma B V
Publication of IL250525A0 publication Critical patent/IL250525A0/en
Publication of IL250525B publication Critical patent/IL250525B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL250525A 2014-08-12 2017-02-09 Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives IL250525B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2014050556 2014-08-12
PCT/NL2015/050555 WO2016024858A1 (en) 2014-08-12 2015-07-29 Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives

Publications (2)

Publication Number Publication Date
IL250525A0 IL250525A0 (en) 2017-03-30
IL250525B true IL250525B (en) 2019-08-29

Family

ID=51429345

Family Applications (1)

Application Number Title Priority Date Filing Date
IL250525A IL250525B (en) 2014-08-12 2017-02-09 Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives

Country Status (28)

Country Link
US (1) US10112904B2 (https=)
EP (2) EP3180314B1 (https=)
JP (1) JP6670310B2 (https=)
KR (1) KR102572626B1 (https=)
CN (1) CN107108558B (https=)
AR (1) AR101509A1 (https=)
AU (1) AU2015302407B2 (https=)
BR (1) BR112017002873B1 (https=)
CA (1) CA2958040C (https=)
CL (1) CL2017000367A1 (https=)
CY (1) CY1125574T1 (https=)
DK (1) DK3180314T3 (https=)
EA (1) EA034357B1 (https=)
ES (1) ES2926775T3 (https=)
HR (1) HRP20221061T1 (https=)
HU (1) HUE059947T2 (https=)
IL (1) IL250525B (https=)
LT (1) LT3180314T (https=)
MA (1) MA40378B1 (https=)
MX (1) MX367908B (https=)
PL (1) PL3180314T3 (https=)
PT (1) PT3180314T (https=)
RS (1) RS63575B1 (https=)
SG (1) SG11201701077XA (https=)
SI (1) SI3180314T1 (https=)
SM (1) SMT202200385T1 (https=)
TW (1) TWI691490B (https=)
WO (1) WO2016024858A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4125911B1 (en) 2021-03-05 2024-04-24 NewAmsterdam Pharma B.V. Obicetrapib for treatment of dementias
IL310115A (en) 2021-07-26 2024-03-01 Newamsterdam Pharma B V Treatment of his hyporesponders
AU2022425078A1 (en) 2021-12-30 2024-08-08 Newamsterdam Pharma B.V. Obicetrapib and sglt2 inhibitor combination
CU20250001A7 (es) 2022-07-05 2025-10-17 Newamsterdam Pharma B V Sales de obicetrapib y procesos para su fabricación y productos intermedios de estos
TW202416994A (zh) 2022-08-22 2024-05-01 荷蘭商新阿姆斯特丹製藥公司 固定劑量醫藥組合物及其用途
EP4661865A1 (en) 2023-02-07 2025-12-17 NewAmsterdam Pharma B.V. Obicetrapib and ezetimibe combination treatment and fixed dose pharmaceutical compositions
WO2025059594A1 (en) 2023-09-15 2025-03-20 Newamsterdam Pharma B.V. METHODS FOR TREATING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HeFH)
WO2025093129A1 (en) 2023-11-01 2025-05-08 Newamsterdam Pharma B.V. Treatment and prevention of age-related macular degeneration using a cetp inhibitor
WO2025093436A1 (en) 2023-11-01 2025-05-08 Newamsterdam Pharma B.V. Treatment and prevention of age-related macular degeneration using a cetp inhibitor
WO2025146262A1 (en) 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Obicetrapib for use in the treatment of hemoglobinopathies
WO2025146415A1 (en) 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Improvement in atherosclerotic plaque characteristics with obicetrapib
WO2026062050A1 (en) 2024-09-17 2026-03-26 Newamsterdam Pharma B.V. Obicetrapib for use in methods for treating a subject having heterozygous familial hypercholesterolemia (hefh) and/or atherosclerotic cardiovascular disease (ascvd)
WO2026062049A1 (en) 2024-09-21 2026-03-26 Newamsterdam Pharma B.V., Obicetrapib for the treatment of dementias
WO2026063944A1 (en) 2024-09-21 2026-03-26 Newamsterdam Pharma B.V. Obicetrapib for the treatment of dementias

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
ATE316957T1 (de) * 2001-04-30 2006-02-15 Pfizer Prod Inc Verbindungen verwendbar als zwischenprodukte für 4-aminochinolinderivate
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
CN101466679A (zh) * 2006-03-30 2009-06-24 田边三菱制药株式会社 制备四氢喹啉衍生物的方法
TW200808731A (en) 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives

Also Published As

Publication number Publication date
JP6670310B2 (ja) 2020-03-18
PT3180314T (pt) 2022-09-02
EP4083022A1 (en) 2022-11-02
EP3180314A1 (en) 2017-06-21
IL250525A0 (en) 2017-03-30
CA2958040A1 (en) 2016-02-18
MX2017001930A (es) 2018-03-01
HRP20221061T1 (hr) 2022-11-25
CN107108558B (zh) 2019-11-19
CN107108558A (zh) 2017-08-29
EA201790364A1 (ru) 2017-07-31
DK3180314T3 (da) 2022-08-29
HUE059947T2 (hu) 2023-01-28
SI3180314T1 (sl) 2022-11-30
JP2017524742A (ja) 2017-08-31
AU2015302407A1 (en) 2017-03-02
AR101509A1 (es) 2016-12-21
TW201613868A (en) 2016-04-16
MX367908B (es) 2019-09-11
CY1125574T1 (el) 2026-02-25
SG11201701077XA (en) 2017-03-30
MA40378A (fr) 2017-06-21
WO2016024858A1 (en) 2016-02-18
MA40378B1 (fr) 2022-10-31
CL2017000367A1 (es) 2018-02-09
BR112017002873A2 (pt) 2018-07-17
LT3180314T (lt) 2022-11-10
CA2958040C (en) 2022-09-13
KR20170102204A (ko) 2017-09-08
US20170267640A1 (en) 2017-09-21
BR112017002873B1 (pt) 2023-03-28
KR102572626B1 (ko) 2023-08-30
PL3180314T3 (pl) 2022-11-21
RS63575B1 (sr) 2022-10-31
AU2015302407B2 (en) 2019-09-19
BR112017002873A8 (pt) 2022-11-08
ES2926775T3 (es) 2022-10-28
TWI691490B (zh) 2020-04-21
SMT202200385T1 (it) 2022-11-18
US10112904B2 (en) 2018-10-30
EA034357B1 (ru) 2020-01-30
EP3180314B1 (en) 2022-06-22

Similar Documents

Publication Publication Date Title
IL250525B (en) Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives
HUE059158T2 (hu) Eljárás pridopidin elõállítására
HUE042409T2 (hu) Eljárás diaril-tiohidantoin vegyület elõállítására
IL264143B (en) Processes for preparing olaparib
BR112016019334A2 (pt) produção de produtos de poliolefina
HUE047041T2 (hu) Eljárás poliéteraminok elõállítására
HUE064612T2 (hu) Eljárás brivaracetam elõállítására
HUE050974T2 (hu) Eljárás pirimidinszulfamid-származékok elõállítására
HUE058257T2 (hu) Eljárások oxatiazin-jellegû vegyületek elõállítására
LT3237432T (lt) Baltymo gamyba
HUE056357T2 (hu) Szobetirom származékok
HUE049170T2 (hu) Eljárás szubsztituált cikloszerinek elõállítására
HUE042349T2 (hu) Eljárás diariltiohidantoin vegyület elõállítására
FR3023290B1 (fr) Derives de flavaglines
HUE053428T2 (hu) Eljárás otikus progenitorok elõállítására
IL250613B (en) Substituted bicyclic compounds
HUE047756T2 (hu) Eljárás metil-merkaptán elõállítására
HUE045704T2 (hu) Eljárás 5-fluor-1H-pirazolok elõállítására hexafluorpropénbõl kiindulva
HUE042493T2 (hu) Újfajta fuzionált imidazobenzotiazol vegyületek
HRP20181805T1 (hr) Postupak za proizvodnju poligvanidina
HUE046518T2 (hu) Cikloalkilcsoporthoz kapcsolt diheterociklusos származékok
LT3097076T (lt) Nauji cip-eikozanoidų dariniai
BR112016027819A2 (pt) Processo de preparação de derivados de tiazole
BR112016027556A2 (pt) métodos de preparação de um composto
FR3024647B1 (fr) Transat de puericulture

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed